LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance
- First-ever quarter of GAAP profitability with net income of $0.6 million
- Total revenues increased 49% YoY to $65.7 million
- Telehealth revenue grew 70% YoY to $52.4 million
- Adjusted EBITDA improved to $8.7 million from $0.1 million YoY
- Strong cash position of $34.4 million
- Raised full-year 2025 guidance for both revenue and adjusted EBITDA
- Exclusive partnerships with LillyDirect and NovoCare for GLP-1 medications
- Gross margin declined to 87% from 90% due to revenue mix and pharmacy launch
- WorkSimpli revenue remained flat YoY
- WorkSimpli active subscribers decreased 5% YoY
Insights
LifeMD achieves first-ever GAAP profitability with 49% revenue growth and significantly improved margins, demonstrating successful business model transformation.
LifeMD's Q1 2025 results represent a critical inflection point in the company's evolution, marking its transition from growth-at-all-costs to profitable expansion. The company reported its first-ever quarter of GAAP profitability ($0.6 million net income or $0.01 EPS), substantially ahead of expectations while simultaneously delivering 49% year-over-year revenue growth to $65.7 million.
The telehealth segment demonstrated exceptional performance with 70% revenue growth to $52.5 million, significantly outpacing the 22% subscriber growth to 290,660 users. This expanding revenue-per-subscriber ratio indicates successful monetization through either higher-value services or increased customer retention.
Most impressive is the dramatic improvement in profitability metrics. Telehealth adjusted EBITDA swung from a $1.3 million loss to $5.3 million profit year-over-year, while overall adjusted EBITDA jumped to $8.7 million from just $0.1 million in Q1 2024. This demonstrates substantial operational leverage in the business model as fixed costs are distributed across higher revenue.
The slight gross margin compression (87% vs 90% last year) appears strategic rather than concerning, resulting from the newly launched pharmacy operations which may enhance customer retention and lifetime value despite near-term margin impact.
Management's decision to raise full-year guidance signals confidence in sustainable momentum. Strategic collaborations with LillyDirect and NovoCare position LifeMD as the only telehealth provider offering cash-pay access to both major GLP-1 medications (Wegovy and Zepbound), creating a compelling competitive advantage in the booming weight management market.
With $34.4 million cash on hand and expansion into mental health, hormone therapy, and women's health verticals, LifeMD appears well-positioned to leverage its telehealth infrastructure across multiple high-value treatment categories while maintaining its newfound profitability.
LifeMD's Q1 results validate their multi-condition telehealth platform strategy that's now generating substantial profitable growth. While many telehealth companies struggled post-pandemic to find sustainable business models, LifeMD has successfully diversified beyond initial direct-to-consumer offerings into a comprehensive virtual care platform.
The company's strategic positioning in the weight management market appears particularly astute. By securing collaborations with both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) for GLP-1 medications, LifeMD has differentiated itself in a highly competitive telehealth landscape. These partnerships likely required demonstrating clinical quality and operational excellence, suggesting pharmaceutical industry validation of their care model.
LifeMD's expansion into men's hormone therapy targets another high-margin specialty area with recurring treatment patterns. Similarly, the company's moves into behavioral health and women's health represent logical adjacencies to capture more comprehensive care opportunities within their existing patient population.
The acceptance of Medicare signals LifeMD's evolution beyond pure cash-pay models into broader reimbursement channels, potentially expanding their addressable market significantly. This multi-payer strategy reduces concentration risk while maintaining the high-margin direct-pay offerings that have driven their financial turnaround.
The reported 22% growth in telehealth subscribers to 290,660 demonstrates sustained consumer demand, but the 70% telehealth revenue growth reveals LifeMD's success in expanding services per customer – a crucial metric for long-term value creation in subscription healthcare models.
While the WorkSimpli segment appears to have plateaued (flat revenue, -5% subscribers), the core telehealth business now shows sufficient momentum to drive overall company performance. The combination of clinical expansion, strategic partnerships, and operational efficiency improvements positions LifeMD at the forefront of sustainable telehealth business models.
- Total revenues increased
49% year-over-year to$65.7 million with telehealth revenue up70% - Adjusted EBITDA increased to
$8.7 million from$0.1 million in the year-ago period - Telehealth adjusted EBITDA increased to
$5.3 million from a loss of$1.3 million in the year-ago period - GAAP net income of
$0.6 million or$0.01 per diluted share, delivering first-ever quarter of positive GAAP EPS - Raising full-year 2025 guidance for both total revenues and adjusted EBITDA, reflecting strong year-to-date performance in telehealth
Conference call begins at 4:30 p.m. Eastern time today
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three months ended March 31, 2025.
Management Commentary
Justin Schreiber, Chairman and CEO of LifeMD, said, “LifeMD had an outstanding first quarter that demonstrated the power of our platform, the need for our services and the accelerated growth trajectory of the business as we achieved our first-ever quarter of GAAP profitability well ahead of expectations. During the quarter we expanded across all service areas, and the performance of our weight management program underscored our success as it is now expected to exceed top- and bottom-line expectations for the full year. The launch of our men’s hormone therapy offering, and recent acceptance of Medicare are also off to strong starts and continue to diversify our already leading telehealth platform.
“Our recently announced strategic collaborations with both LillyDirect and NovoCare continue to generate momentum by allowing us to offer more convenient and affordable access to branded GLP-1 medications. These collaborations make LifeMD the only telehealth provider in the U.S. that offers synchronous care and cash-pay access to both Wegovy® and Zepbound®. In addition to the continued success of our existing telehealth platforms, we recently announced key hires in the mental and hormonal health verticals and the acquisition of important assets in behavioral health and women’s health. These are two strategic areas with significant unmet clinical need in the marketplace and within our existing patient population,” concluded Schreiber.
“LifeMD had an exceptionally strong first quarter with top- and bottom-line growth both ahead of our expectations. Telehealth revenue achieved
First Quarter Financial Highlights
All comparisons are with the first quarter of 2024. Non-GAAP financial measures referenced in the following results are defined and reconciled to GAAP at the end of this press release.
- Total revenues increased
49% to$65.7 million with telehealth revenue up70% . - Telehealth active subscribers increased
22% to approximately 290,000 active subscribers. - Gross margin was
87% compared with90% , down slightly due to revenue mix and LifeMD’s recently launched pharmacy. - GAAP net income was
$0.6 million or$0.01 per diluted share, compared with a net loss of$7.5 million or ($0.19) per share. - Adjusted EBITDA was
$8.7 million compared with$0.1 million . - The telehealth business achieved adjusted EBITDA of
$5.3 million compared with a loss of$1.3 million . - Cash was
$34.4 million as of March 31, 2025.
First Quarter Key Performance Metrics
| ($ in 000s) | Three Months Ended March 31, | Y-o-Y | |
| Key Performance Metrics | 2025 | 2024 | % Growth |
| Revenue | |||
| Telehealth | |||
| WorkSimpli | |||
| Total Revenue | $65,698 | $44,144 | 49% |
| Active Subscribers | |||
| Telehealth Active Subscribers | 290,660 | 237,790 | |
| WorkSimpli Active Subscribers | 158,265 | 166,351 | - |
| Total Active Subscribers | 448,925 | 404,141 | 11% |
Financial Guidance
For the second quarter of 2025, the Company expects:
- Total revenues in the range of
$65 million to$67 million , with telehealth revenue in the range of$52 million to$53 million . - Adjusted EBITDA in the range of
$7 million to$9 million , with telehealth adjusted EBITDA in the range of$4 million to$6 million .
For the full year 2025, due to the outperformance of its telehealth business in the first quarter the Company is raising its previous guidance to:
- Total revenues in the range of
$268 million to$275 million , up from previous guidance of$265 million to$275 million . - Telehealth revenue in the range of
$208 million to$213 million , up from$205 million to$213 million . - Adjusted EBITDA in the range of
$31 million to$33 million , up from$30 million to$32 million . - Telehealth adjusted EBITDA is now forecast to exceed
$21 million , up from approximately$20 million previously.
Conference Call
LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:
| Toll-free dial-in number: | 800-225-9448 |
| International dial-in number: | 203-518-9708 |
| Conference ID: | LIFEMD |
| Live & Archived Webcast: | Link |
A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.
About LifeMD
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact
Jessica Friedeman, Chief Marketing Officer
press@lifemd.com
Tables to Follow
| LIFEMD, INC. | |||||||
| CONSOLIDATED BALANCE SHEETS | |||||||
| March 31, 2025 | December 31, 2024 | ||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current Assets | |||||||
| Cash | $ | 34,393,410 | $ | 35,004,924 | |||
| Accounts receivable, net | 10,192,774 | 8,217,813 | |||||
| Product deposit | 191,840 | 40,763 | |||||
| Inventory, net | 2,967,697 | 2,797,358 | |||||
| Other current assets | 2,227,200 | 2,672,231 | |||||
| Total Current Assets | 49,972,921 | 48,733,089 | |||||
| Non-current Assets | |||||||
| Equipment, net | 1,438,829 | 1,479,184 | |||||
| Right of use assets | 6,104,863 | 6,400,596 | |||||
| Capitalized software, net | 14,311,592 | 13,816,501 | |||||
| Intangible assets, net | 1,786,128 | 2,030,656 | |||||
| Total Non-current Assets | 23,641,412 | 23,726,937 | |||||
| Total Assets | $ | 73,614,333 | $ | 72,460,026 | |||
| LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT) | |||||||
| Current Liabilities | |||||||
| Accounts payable | $ | 15,679,028 | $ | 16,009,484 | |||
| Accrued expenses | 18,503,380 | 20,811,764 | |||||
| Current operating lease liabilities | 482,139 | 508,537 | |||||
| Current portion of long-term debt | 11,611,111 | 8,444,444 | |||||
| Deferred revenue | 14,625,902 | 14,480,917 | |||||
| Total Current Liabilities | 60,901,560 | 60,255,146 | |||||
| Long-term Liabilities | |||||||
| Long-term debt, net | 6,818,835 | 9,885,057 | |||||
| Noncurrent operating lease liabilities | 6,186,692 | 6,265,192 | |||||
| Contingent consideration | 100,000 | 100,000 | |||||
| Total Liabilities | 74,007,087 | 76,505,395 | |||||
| Commitments and Contingencies | |||||||
| Mezzanine Equity | |||||||
| Preferred Stock, Series B Convertible Preferred Stock, | - | - | |||||
| Stockholders’ Equity (Deficit) | |||||||
| Series A Preferred Stock, | 140 | 140 | |||||
| Common Stock, | 436,327 | 422,939 | |||||
| Additional paid-in capital | 233,043,479 | 230,508,339 | |||||
| Accumulated deficit | (235,644,977 | ) | (236,253,218 | ) | |||
| Treasury stock, 103,040 shares, at cost, as of March 31, 2025 and December 31, 2024 | (163,701 | ) | (163,701 | ) | |||
| Total LifeMD, Inc. Stockholders’ Deficit | (2,328,732 | ) | (5,485,501 | ) | |||
| Non-controlling interest | 1,935,978 | 1,440,132 | |||||
| Total Stockholders’ Equity (Deficit) | (392,754 | ) | (4,045,369 | ) | |||
| Total Liabilities, Mezzanine Equity and Stockholders’ Equity (Deficit) | $ | 73,614,333 | $ | 72,460,026 | |||
| LIFEMD, INC. | |||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
| (Unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Revenues | |||||||
| Telehealth revenue, net | $ | 52,456,481 | $ | 30,841,402 | |||
| WorkSimpli revenue, net | 13,241,275 | 13,302,862 | |||||
| Total revenues, net | 65,697,756 | 44,144,264 | |||||
| Cost of revenues | |||||||
| Cost of telehealth revenue | 8,136,462 | 4,194,595 | |||||
| Cost of WorkSimpli revenue | 507,254 | 405,582 | |||||
| Total cost of revenues | 8,643,716 | 4,600,177 | |||||
| Gross profit | 57,054,040 | 39,544,087 | |||||
| Expenses | |||||||
| Selling and marketing expenses | 29,194,061 | 24,173,880 | |||||
| General and administrative expenses | 17,055,669 | 15,305,732 | |||||
| Customer service expenses | 3,071,494 | 1,848,041 | |||||
| Development costs | 2,675,134 | 2,087,232 | |||||
| Other operating expenses | 2,514,758 | 2,300,447 | |||||
| Total expenses | 54,511,116 | 45,715,332 | |||||
| Operating income (loss) | 2,542,924 | (6,171,245 | ) | ||||
| Other expenses | |||||||
| Interest expense, net | (626,275 | ) | (477,678 | ) | |||
| Net income (loss) before income taxes | 1,916,649 | (6,648,923 | ) | ||||
| Income tax expense | - | - | |||||
| Net income (loss) | 1,916,649 | (6,648,923 | ) | ||||
| Net income attributable to noncontrolling interests | 531,845 | 119,432 | |||||
| Net income (loss) attributable to LifeMD, Inc. | 1,384,804 | (6,768,355 | ) | ||||
| Preferred stock dividends | (776,563 | ) | (776,563 | ) | |||
| Net income (loss) attributable to LifeMD, Inc. common stockholders | $ | 608,241 | $ | (7,544,918 | ) | ||
| Basic earnings (loss) per share attributable to LifeMD, Inc. common stockholders | $ | 0.01 | $ | (0.19 | ) | ||
| Diluted earnings (loss) per share attributable to LifeMD, Inc. common stockholders | $ | 0.01 | $ | (0.19 | ) | ||
| Weighted average number of common shares outstanding: | |||||||
| Basic | 43,135,778 | 39,242,237 | |||||
| Diluted | 45,580,311 | 39,242,237 | |||||
| LIFEMD, INC. | |||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| (Unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||||
| Net income (loss) | $ | 1,916,649 | $ | (6,648,923 | ) | ||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||
| Amortization of debt discount | 100,444 | 100,444 | |||||
| Amortization of capitalized software | 2,250,036 | 1,787,404 | |||||
| Amortization of intangibles | 244,528 | 245,966 | |||||
| Accretion of consideration payable | - | 13,644 | |||||
| Depreciation of fixed assets | 162,566 | 65,915 | |||||
| Noncash operating lease expense | 295,733 | 206,809 | |||||
| Stock compensation expense | 2,548,528 | 2,544,430 | |||||
| Changes in Assets and Liabilities | |||||||
| Accounts receivable | (1,974,961 | ) | (59,241 | ) | |||
| Product deposit | (151,077 | ) | 196,912 | ||||
| Inventory | (170,339 | ) | 386,292 | ||||
| Other current assets | 445,031 | (364,227 | ) | ||||
| Operating lease liabilities | (104,897 | ) | (203,944 | ) | |||
| Deferred revenue | 144,985 | 4,374,159 | |||||
| Accounts payable | (330,456 | ) | 1,310,177 | ||||
| Accrued expenses | (2,308,383 | ) | 1,246,342 | ||||
| Net cash provided by operating activities | 3,068,387 | 5,202,159 | |||||
| (53,393 | ) | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||||
| Cash paid for capitalized software costs | (2,745,127 | ) | (2,014,673 | ) | |||
| Purchase of equipment | (122,211 | ) | (175,592 | ) | |||
| Net cash used in investing activities | (2,867,338 | ) | (2,190,265 | ) | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||||
| Repayment of notes payable, net of prepayment penalty | - | (211,690 | ) | ||||
| Cash proceeds from exercise of options | - | 7,813 | |||||
| Preferred stock dividends | (776,563 | ) | (776,563 | ) | |||
| Contingent consideration payment for ResumeBuild | - | (31,250 | ) | ||||
| Distributions to non-controlling interest | (36,000 | ) | (36,000 | ) | |||
| Net cah used in financing activities | (812,563 | ) | (1,047,690 | ) | |||
| Net (decrease) increase in cash | (611,514 | ) | 1,964,204 | ||||
| Cash at beginning of period | 35,004,924 | 33,146,725 | |||||
| Cash at end of period | $ | 34,393,410 | $ | 35,110,929 | |||
| Cash paid for interest | |||||||
| Cash paid during the period for interest | $ | 593,750 | $ | 644,919 | |||
| Non-cash investing and financing activities: | |||||||
| Cashless exercise of options | $ | 561 | $ | 641 | |||
| Cashless exercise of warrants | $ | - | $ | 12,685 | |||
| Stock issued for noncontingent consideration payments | $ | - | $ | 642,000 | |||
| Right of use asset | $ | - | $ | 1,285,926 | |||
| Right of use lease liability | $ | - | $ | 1,285,926 | |||
About the Use of Non-GAAP Financial Measures:
To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. Additionally, we report telehealth adjusted EBITDA as a non-GAAP financial measure to clarify the financial performance of our core telehealth business excluding WorkSimpli. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.
Adjusted EBITDA is defined as income (loss) attributable to common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests, foreign currency translation, extraordinary litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to common shareholders, its most directly comparable GAAP financial measure.
Telehealth and WorkSimpli adjusted EBITDA is defined as segment operating income or loss before depreciation, amortization, accretion, financing transaction expense, extraordinary litigation costs, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of segment operating income or loss to segment Adjusted EBITDA.
We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted EBITDA may vary from that of others in our industry. Telehealth adjusted EBITDA is specifically relevant to LifeMD to provide shareholders a comparable measure of profitability for our core telehealth business without the impact of our majority owned, but separately managed non-core subsidiary, WorkSimpli. Adjusted EBITDA, telehealth adjusted EBITDA and WorkSimpli adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.
| Reconciliation of Consolidated GAAP Net Income (Loss) to Consolidated Adjusted EBITDA | ||||||
| (in whole numbers, unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Net income (loss) attributable to common shareholders | $ | 608,241 | $ | (7,544,918 | ) | |
| Interest expense (excluding amortization of debt discount) | 525,831 | 377,234 | ||||
| Depreciation, amortization and accretion expense | 2,657,130 | 2,112,929 | ||||
| Amortization of debt discount | 100,444 | 100,444 | ||||
| Financing transactions expense | - | 172,229 | ||||
| Litigation costs (a) | 253,197 | 182,547 | ||||
| Severance costs | 76,882 | 160,495 | ||||
| Acquisitions expenses | 208,500 | - | ||||
| Insurance acceptance readiness | 140,360 | 706,341 | ||||
| Sarbanes Oxley readiness | - | 159,908 | ||||
| Foreign exchange loss (gain) | 231,647 | (26,248 | ) | |||
| Taxes | - | - | ||||
| Dividends | 776,563 | 1,043,380 | ||||
| Stock-based compensation expense | 2,548,528 | 2,544,430 | ||||
| Net income attributable to noncontrolling interests | 531,845 | 119,432 | ||||
| Consolidated Adjusted EBITDA | $ | 8,659,168 | $ | 108,203 | ||
| (a) For the three months ended March 31, 2025, the Company included litigation costs related to a heavily negotiated executive separation agreement. For the three months ended March 31, 2024, the Company included costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), as disclosed in the Company’s Form 10-Q for the three months ended March 31, 2025, filed on May 6, 2025, and a heavily negotiated executive separation agreement. | ||||||
| Reconciliation of Telehealth GAAP Operating Income (Loss) to Telehealth Adjusted EBITDA | ||||||
| (in whole numbers, unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Telehealth operating income (loss) | $ | 386,865 | $ | (6,619,763 | ) | |
| Depreciation, amortization and accretion expense | 1,691,409 | 1,363,074 | ||||
| Financing transactions expense | - | 172,229 | ||||
| Litigation costs (a) | 253,197 | 182,547 | ||||
| Severance costs | 76,882 | 160,495 | ||||
| Acquisitions expenses | 208,500 | - | ||||
| Insurance acceptance readiness | 140,360 | 706,341 | ||||
| Sarbanes Oxley readiness | - | 159,908 | ||||
| Stock-based compensation expense | 2,548,528 | 2,544,430 | ||||
| Telehealth Adjusted EBITDA | $ | 5,305,741 | $ | (1,330,739 | ) | |
| (a) For the three months ended March 31, 2025, the Company included litigation costs related to a heavily negotiated executive separation agreement. For the three months ended March 31, 2024, the Company included costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), as disclosed in the Company’s Form 10-Q for the three months ended March 31, 2025, filed on May 6, 2025, and a heavily negotiated executive separation agreement. | ||||||
| Reconciliation of WorkSimpli GAAP Operating Income to WorkSimpli Adjusted EBITDA | ||||||
| (in whole numbers, unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| 2025 | 2024 | |||||
| WorkSimpli operating income | $ | 2,156,059 | $ | 448,518 | ||
| Depreciation, amortization and accretion expense | 965,721 | 749,855 | ||||
| Foreign exchange loss (gain) | 231,647 | (26,248 | ) | |||
| Distributions | - | 266,817 | ||||
| WorkSimpli Adjusted EBITDA | $ | 3,353,427 | $ | 1,438,942 | ||
FAQ
What were LifeMD's (LFMD) Q1 2025 earnings results?
How much did LifeMD's (LFMD) telehealth revenue grow in Q1 2025?
What is LifeMD's (LFMD) full-year 2025 guidance?
What strategic partnerships did LifeMD (LFMD) announce for GLP-1 medications?
How much cash does LifeMD (LFMD) have on its balance sheet?
